8-K Announcements
6Material company update
Mar 11, 2026·SEC
Material company update
Mar 5, 2026·SEC
Material company update
Jan 30, 2026·SEC
Tenaya Therapeutics, Inc.(TNYA)Earnings, Financials & Key Ratios
TNYA•NASDAQ
$0.85
$184M mkt cap·Price updated May 7, 2026
AboutTenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$85M+21.0%
- Net Income-$91M+18.5%
- EPS (Diluted)-0.59+55.0%
- ROE-83.84%+12.4%
- ROIC-103.18%-23.6%
- Debt/Equity0.09-40.0%
TNYA Key Insights
Tenaya Therapeutics, Inc. (TNYA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 1.1x book value
✗Weaknesses
- ✗Shares diluted 80.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TNYA Price & Volume
Tenaya Therapeutics, Inc. (TNYA) stock price & volume — 10-year historical chart
Loading chart...
TNYA Growth Metrics
Tenaya Therapeutics, Inc. (TNYA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM18.48%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM53.03%
Return on Capital
10 Years-63.04%
5 Years-63.11%
3 Years-78.86%
Last Year-79.28%
TNYA Recent Earnings
Tenaya Therapeutics, Inc. (TNYA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)
Q2 2026Latest
Mar 11, 2026EPS
$0.12
Est $0.13
+7.7%
Revenue
—
Est $3M
Q4 2025
Nov 10, 2025EPS
$0.12
Est $0.15
+20.0%
Revenue
—
Q3 2025
Aug 6, 2025EPS
$0.14
Est $0.20
+30.0%
Revenue
—
Q2 2025
May 7, 2025EPS
$0.24
Est $0.18
-33.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 11, 2026 | $0.12vs $0.13+7.7% | —vs $3M |
| Q4 2025 | Nov 10, 2025 | $0.12vs $0.15+20.0% | — |
| Q3 2025 | Aug 6, 2025 | $0.14vs $0.20+30.0% | — |
| Q2 2025 | May 7, 2025 | $0.24vs $0.18-33.3% | — |
Based on last 12 quarters of dataView full earnings history →
TNYA Peer Comparison
Tenaya Therapeutics, Inc. (TNYA) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCKT | 397.53M | 3.67 | -1.83 | -80.49% | 0.09 | |||
 SGMO | 21.54M | 0.10 | -0.21 | -67.2% | -331.28% | -8.14% | 1.34 | |
 EDIT | 296.54M | 3.03 | -1.68 | -100% | -5.23% | 0.66 | ||
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 | |
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 | |
 CRSP | 5.06B | 52.42 | -8.10 | -89.97% | -138.57% | -30.88% | 0.21 | |
 ARWR | 10.92B | 77.95 | -6389.34 | 232.58% | -48.38% | -55.47% | 0.73 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 |
Compare TNYA vs Peers
Tenaya Therapeutics, Inc. (TNYA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TNYA Income Statement
Tenaya Therapeutics, Inc. (TNYA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 1.99M | 2.48M | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -1.99M▲ 0% | -2.48M▼ 24.8% | -4.03M▼ 62.1% | -8.71M▼ 116.5% | -8.69M▲ 0.3% | -8.47M▲ 2.5% | -8.44M▲ 0.4% |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -24.84% | -62.1% | -116.47% | 0.3% | 2.52% | 0.38% |
| Operating Expenses | 27.71M | 36.43M | 68.78M | 116.91M | 122.51M | 107.48M | 84.89M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 4.56M | 5.33M | 14.39M | 22.37M | 24.47M | 20.74M | 24.72M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 23.15M | 31.1M | 54.39M | 94.54M | 98.04M | 86.74M | 68.61M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 1.03M | 0 | 0 | 0 | 0 | 0 | -8.44M |
| Operating Income | -27.71M▲ 0% | -38.91M▼ 40.4% | -72.81M▼ 87.1% | -125.62M▼ 72.5% | -131.19M▼ 4.4% | -115.95M▲ 11.6% | -93.33M▲ 19.5% |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -40.42% | -87.1% | -72.54% | -4.44% | 11.62% | 19.51% |
| EBITDA | -25.72M | -36.43M | -68.78M | -116.91M | -122.51M | -107.48M | -84.89M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -41.62% | -88.81% | -69.97% | -4.79% | 12.27% | 21.01% |
| D&A (Non-Cash Add-back) | 1.99M | 2.48M | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| EBIT | -27.71M | -38.4M | -72.72M | -123.67M | -124.08M | -111.13M | -93.33M |
| Net Interest Income | 453K | 87K | 108K | 1.95M | 7.06M | 4.74M | 2.68M |
| Interest Income | 453K | 87K | 108K | 1.95M | 7.06M | 4.74M | 2.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 1.48M | 517K | 85K | 1.96M | 7.11M | 4.82M | 2.73M |
| Pretax Income | -26.23M▲ 0% | -38.4M▼ 46.4% | -72.72M▼ 89.4% | -123.67M▼ 70.1% | -124.08M▼ 0.3% | -111.13M▲ 10.4% | -90.6M▲ 18.5% |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -25.78M▲ 0% | -38.4M▼ 48.9% | -72.72M▼ 89.4% | -123.67M▼ 70.1% | -124.08M▼ 0.3% | -111.13M▲ 10.4% | -90.6M▲ 18.5% |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -48.94% | -89.4% | -70.05% | -0.34% | 10.44% | 18.48% |
| Net Income (Continuing) | -26.23M | -38.4M | -72.72M | -123.67M | -124.08M | -111.13M | -90.6M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.95▲ 0% | -0.93▲ 2.1% | -1.69▼ 81.7% | -2.76▼ 63.3% | -1.68▲ 39.1% | -1.31▲ 22.0% | -0.59▲ 55.0% |
| EPS Growth % | - | 2.11% | -81.72% | -63.31% | 39.13% | 22.02% | 54.96% |
| EPS (Basic) | -0.95 | -0.93 | -1.69 | -2.76 | -1.68 | -1.31 | -0.59 |
| Diluted Shares Outstanding | 27.2M | 41.12M | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
| Basic Shares Outstanding | 27.2M | 41.12M | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
TNYA Balance Sheet
Tenaya Therapeutics, Inc. (TNYA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 27.74M | 129.96M | 255.36M | 193.75M | 111.58M | 67.38M | 105.59M |
| Cash & Short-Term Investments | 26.63M | 128.53M | 251.3M | 186.53M | 104.64M | 61.45M | 100.55M |
| Cash Only | 23.87M | 128.53M | 38.13M | 95.27M | 45.68M | 4.32M | 100.55M |
| Short-Term Investments | 2.75M | 0 | 213.17M | 91.25M | 58.96M | 57.12M | 0 |
| Accounts Receivable | 0 | 0 | 0 | 2.25M | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 4.06M | 938K | 1.16M | 842K | 5.04M |
| Total Non-Current Assets | 10.26M | 18.2M | 61.29M | 85.19M | 58.93M | 52.56M | 41.34M |
| Property, Plant & Equipment | 9.57M | 17.18M | 54.7M | 62.7M | 53.26M | 47.75M | 37.09M |
| Fixed Asset Turnover | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 485K | 0 | 547K | 17.7M | 0 | 0 | 419K |
| Other Non-Current Assets | 199K | 1.01M | 3.58M | 4.79M | 5.68M | 4.82M | 3.83M |
| Total Assets | 38M▲ 0% | 148.16M▲ 289.9% | 316.65M▲ 113.7% | 278.94M▼ 11.9% | 170.51M▼ 38.9% | 119.94M▼ 29.7% | 146.92M▲ 22.5% |
| Asset Turnover | - | - | - | - | - | - | - |
| Asset Growth % | - | 289.89% | 113.72% | -11.91% | -38.87% | -29.66% | 22.5% |
| Total Current Liabilities | 4.12M | 5.04M | 21.77M | 24.25M | 22.73M | 15.97M | 15.44M |
| Accounts Payable | 600K | 1.02M | 10.72M | 9.58M | 5.63M | 5.16M | 3.58M |
| Days Payables Outstanding | 110.11 | 149.5 | 972.21 | 401.24 | 236.55 | 222.5 | 154.94 |
| Short-Term Debt | 0 | 0 | 1.99M | 0 | 0 | 2.78M | 3.02M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.94M | 1.22M | 5.39M | 6.97M | 9.27M | 5.81M | 8.56M |
| Current Ratio | 6.73x | 25.78x | 11.73x | 7.99x | 4.91x | 4.22x | 6.84x |
| Quick Ratio | 6.73x | 25.78x | 11.73x | 7.99x | 4.91x | 4.22x | 6.84x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 77.62M | 3.68M | 16.35M | 11.32M | 8.36M | 11.11M | 8.22M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 7.81M |
| Capital Lease Obligations | 0 | 0 | 13.71M | 11.09M | 8.11M | 10.83M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 2.46M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 77.62M | 3.68M | 182K | 228K | 253K | 281K | 410K |
| Total Liabilities | 81.74M | 8.72M | 38.12M | 35.57M | 31.09M | 27.09M | 23.66M |
| Total Debt | 0 | 0 | 15.7M | 15.1M | 12.42M | 13.61M | 10.83M |
| Net Debt | -23.87M | -128.53M | -22.43M | -80.17M | -33.26M | 9.29M | -89.72M |
| Debt / Equity | - | - | 0.06x | 0.06x | 0.09x | 0.15x | 0.09x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - |
| Total Equity | -43.74M▲ 0% | 139.44M▲ 418.8% | 278.53M▲ 99.7% | 243.38M▼ 12.6% | 139.42M▼ 42.7% | 92.85M▼ 33.4% | 123.27M▲ 32.8% |
| Equity Growth % | - | 418.8% | 99.75% | -12.62% | -42.71% | -33.4% | 32.75% |
| Book Value per Share | -1.61 | 3.39 | 6.75 | 5.43 | 1.89 | 1.09 | 0.81 |
| Total Shareholders' Equity | -43.74M | 139.44M | 278.53M | 243.38M | 139.42M | 92.85M | 123.27M |
| Common Stock | 1K | 0 | 4K | 7K | 7K | 8K | 21K |
| Retained Earnings | -44.42M | -82.81M | -155.53M | -279.2M | -403.28M | -514.41M | -605.01M |
| Treasury Stock | 12.96K | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -74.04K | -87K | -141K | -378K | -106K | 28K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TNYA Cash Flow Statement
Tenaya Therapeutics, Inc. (TNYA) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -24.1M | -35.45M | -60.81M | -104.42M | -102.07M | -90.5M | -68.26M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -47.11% | -71.56% | -71.72% | 2.25% | 11.34% | 24.57% |
| Net Income | -26.23M | -38.4M | -72.72M | -123.67M | -124.08M | -111.13M | -90.6M |
| Depreciation & Amortization | 1.99M | 2.48M | 2.96M | 6.47M | 8.69M | 8.47M | 8.85M |
| Stock-Based Compensation | 414K | 741K | 2.95M | 11.47M | 15.31M | 16.5M | 13.05M |
| Deferred Taxes | -82K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 64K | -42K | 1.26M | 2.16M | 3.66M | 3.59M | 2.9M |
| Working Capital Changes | -250K | -234K | 4.74M | -849K | -5.65M | -7.93M | -2.46M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 397K | 142K | 8.6M | 1.66M | -3.28M | -581K | -1.43M |
| Cash from Investing | -5.58M | -7.01M | -238.56M | 83.65M | 48.72M | 1.13M | 56.08M |
| Capital Expenditures | -2.93M | -9.76M | -25.12M | -20.63M | -1.24M | -1.02M | -618K |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | 2.66K | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -2.66K | 0 | 0 | 8K | -25K | 17K | 0 |
| Cash from Financing | 30.51M | 147.27M | 208.97M | 77.77M | 4.05M | 47.75M | 108.41M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -3K | -1K | -13K | 0 | 0 | 0 | 0 |
| Other Financing | 68K | 34K | 461K | 380K | 181K | 987K | 0 |
| Net Change in Cash | 832K▲ 0% | 104.81M▲ 12497.5% | -90.41M▼ 186.3% | 56.99M▲ 163.0% | -49.31M▼ 186.5% | -41.62M▲ 15.6% | 96.22M▲ 331.2% |
| Free Cash Flow | -27.02M▲ 0% | -45.21M▼ 67.3% | -85.93M▼ 90.1% | -125.05M▼ 45.5% | -103.31M▲ 17.4% | -91.53M▲ 11.4% | -68.88M▲ 24.7% |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -67.31% | -90.08% | -45.52% | 17.39% | 11.41% | 24.74% |
| FCF per Share | -0.99 | -1.10 | -2.08 | -2.79 | -1.40 | -1.08 | -0.45 |
| FCF Conversion (FCF/Net Income) | 0.93x | 0.92x | 0.84x | 0.84x | 0.82x | 0.81x | 0.75x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TNYA Key Ratios
Tenaya Therapeutics, Inc. (TNYA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -80.24% | -34.8% | -47.39% | -64.83% | -95.69% | -83.84% |
| Return on Invested Capital (ROIC) | - | - | -40.9% | -44.94% | -73.06% | -83.49% | -103.18% |
| Debt / Equity | - | - | 0.06x | 0.06x | 0.09x | 0.15x | 0.09x |
| FCF Conversion | 0.93x | 0.92x | 0.84x | 0.84x | 0.82x | 0.81x | 0.75x |
TNYA SEC Filings & Documents
Tenaya Therapeutics, Inc. (TNYA) SEC filings — annual & quarterly reports (10-K, 10-Q)
TNYA Frequently Asked Questions
Tenaya Therapeutics, Inc. (TNYA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Tenaya Therapeutics, Inc. (TNYA) grew revenue by 0.0% over the past year. Growth has been modest.
Tenaya Therapeutics, Inc. (TNYA) reported a net loss of $90.6M for fiscal year 2025.
Dividend & Returns
Tenaya Therapeutics, Inc. (TNYA) has a return on equity (ROE) of -83.8%. Negative ROE indicates the company is unprofitable.
Tenaya Therapeutics, Inc. (TNYA) had negative free cash flow of $68.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More TNYA
Tenaya Therapeutics, Inc. (TNYA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates